A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis

Atherosclerosis Supplements

Volumn 6, Issue 4, 2005, Pages 41-46

  Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Cilostazol; CREST; Endothelial cells; HGF; Restenosis; Stenting

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CYCLIC AMP; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PROTEIN P21; PROTEIN P53; SCATTER FACTOR;

ANGIOCARDIOGRAPHY; APOPTOSIS; BIOACCUMULATION; CELL CYCLE ARREST; CELL REGENERATION; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HUMAN; IN-STENT RESTENOSIS; METHODOLOGY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 32944461243     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2005.09.007     Document Type: Article

References (26)

1. M.J. Cowley, G.W. Vetrovec, and T.C. Wolfgang Efficacy of percutaneous transluminal coronary angioplasty: technique, patient selection, salutary results, limitations and complications Am Heart J 101 1981 272 280
2. G.S. Mintz, J.J. Popma, and A.D. Pichard Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study Circulation 94 1996 35 43
3. J.S. Douglas, W.S. Weintraub, and D. Holmes Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial Clin Cardiol 26 2003 451 454
4. J.S. Douglas, D.R. Holmes Jr., and D. Kereiakes Cilostazol for Restenosis trial: a randomized, double-blind study following coronary artery stent implantation [abstract] Circulation 108 2003 4 [A]
5. W.S. Weintraub, J. Foster, and S.D. Culler Methods for the economic and quality of life supplement to the Cilostazol for RESTenosis (CREST) trial J Invasive Cardiol 16 2004 257 259
6. C. Ito, E. Kusano, and Y. Furukawa Modulation of the erythropoietin- induced proliferative pathway by cAMP in vascular smooth muscle cells Am J Physiol Cell Physiol 283 2002 C1715 C1721
7. S. Hayashi, R. Morishita, and H. Matsushita Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21 Hypertension 35 2000 237 243
8. R.R. Reinhardt, E. Chin, and J. Zhou Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases J Clin Invest 95 1995 1528 1538
9. J. Kambayashi, Y. Liu, and B. Sun Cilostazol as a unique antithrombotic agent Curr Pharm Des 9 2003 2289 2302
10. T. Tanaka, T. Ishikawa, and M. Hagiwara Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle Pharmacology 36 1988 313 320
11. D.L. Dawson, B.S. Cutler, M.H. Meissner, and D.E. Strandness Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial Circulation 98 1988 678 686
12. J.A. Smith Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication Clin Cardiol 25 2002 91 94
13. S. Ohashi, M. Iwatani, Y. Hyakuna, and Y. Morioka Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion Arzneimittelforschung 35 1985 1203 1208
14. R. Morishita, G.H. Gibbons, and K.E. Ellison Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia Proc Natl Acad Sci USA 90 1993 8474 8478
15. H. Matsushita, R. Morishita, and I. Kida Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis Hypertension 31 1998 493 498
16. K. Hayashi, S. Nakamura, and R. Morishita In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model Gene Ther 7 2000 1664 1671
17. M. Aoki, R. Morishita, and S. Hayashi Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model Diabetologia 44 2001 1034 1042
18. E.L. Schiffrin, and R.M. Touyz Vascular biology of endothelin J Cardiovasc Pharmacol 32 1998 S2 S13
19. A.H. Dorafshar, N. Angle, and M. Bryer-Ash Vascular endothelial growth factor inhibits mitogen-induced vascular smooth muscle cell proliferation J Surg Res 114 2003 179 186
20. T. Nakamura, T. Nishizawa, and M. Hagiya Molecular cloning and expression of human hepatocyte growth factor Nature 342 1989 440 443
21. Y. Nakamura, R. Morishita, and J. Higaki Hepatocyte growth factor is a novel member of endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with fibroblast growth factor but not with vascular endothelial growth factor J Hypertens 14 1996 1067 1072
22. N. Nakano, R. Morishita, and A. Moriguchi Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease Hypertension 32 1998 444 451
23. R. Morishita, J. Higaki, and S.I. Hayashi Role of hepatocyte growth factor in endothelial regulation: prevention of high d-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor Diabetologia 40 1997 1053 1061
24. E. Tsuchikane, T. Kobayashi, and T. Kobayashi Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT) Am J Cardiol 90 2002 573 578
25. E. Tsuchikane, A. Fukuhara, and T. Kobayashi Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty Circulation 100 1999 21 26
26. T. Igawa, T. Tani, and T. Chijiwa Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells Thromb Res 57 1990 617 623